BG
GEVA

BlackRock Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BlackRock Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-9,522
Closed -$929K – 2997
2015
Q1 		$929K Buy
9,522
+5,188
+120% +$549K ﹤0.01% 1906
2014
Q4 		$402K Buy
4,334
+259
+6% +$20.4K ﹤0.01% 2311
2014
Q3 		$281K Sell
4,075
-74
-2% -$5.3K ﹤0.01% 2361
2014
Q2 		$435K Sell
4,149
-4,622
-53% -$393K ﹤0.01% 2253
2014
Q1 		$727K Sell
8,771
-30,216
-78% -$2.79M ﹤0.01% 2115
2013
Q4 		$2.52M Buy
38,987
+2,909
+8% +$173K ﹤0.01% 1378
2013
Q3 		$2.29M Sell
36,078
-26,300
-42% -$1.29M ﹤0.01% 1404
2013
Q2 		$2.62M Buy
+62,378
New +$2.84M ﹤0.01% 1183

BlackRock Group's GEVA Position: Q2 2015 in Review

BlackRock Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 9,522 shares — an estimated $929K sold.

BlackRock Group first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.62M in Q2 2013. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • BlackRock Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • BlackRock Group sold 9,522 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $929K.
  • BlackRock Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • BlackRock Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.62M in Q2 2013.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BlackRock Group's 13F filing for Q2 2015, filed 7 Aug 2015.